Silvia Rivara

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1465195/publications.pdf

Version: 2024-02-01

125 papers	4,843 citations	76326 40 h-index	114465 63 g-index
131 all docs	131 docs citations	131 times ranked	5171 citing authors

#	Article	IF	Citations
1	In silico drug discovery of melatonin receptor ligands with therapeutic potential. Expert Opinion on Drug Discovery, 2022, 17, 343-354.	5.0	5
2	Free-Energy Simulations Support a Lipophilic Binding Route for Melatonin Receptors. Journal of Chemical Information and Modeling, 2022, 62, 210-222.	5.4	6
3	Mechanistic Modeling of Monoglyceride Lipase Covalent Modification Elucidates the Role of Leaving Group Expulsion and Discriminates Inhibitors with High and Low Potency. Journal of Chemical Information and Modeling, 2022, 62, 2771-2787.	5.4	2
4	New Coumarin Derivatives as Cholinergic and Cannabinoid System Modulators. Molecules, 2021, 26, 3254.	3.8	8
5	Nâ€(Anilinoethyl)amide Melatonergic Ligands with Improved Water Solubility and Metabolic Stability. ChemMedChem, 2021, 16, 3071-3082.	3.2	6
6	Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma. European Journal of Medicinal Chemistry, 2021, 221, 113529.	5.5	3
7	A sulfonyl fluoride derivative inhibits EGFRL858R/T790M/C797S by covalent modification of the catalytic lysine. European Journal of Medicinal Chemistry, 2021, 225, 113786.	5.5	28
8	Benzisothiazolinone Derivatives as Potent Allosteric Monoacylglycerol Lipase Inhibitors That Functionally Mimic Sulfenylation of Regulatory Cysteines. Journal of Medicinal Chemistry, 2020, 63, 1261-1280.	6.4	9
9	N-Acylethanolamine Acid Amidase (NAAA): Mechanism of Palmitoylethanolamide Hydrolysis Revealed by Mechanistic Simulations. ACS Catalysis, 2020, 10, 11797-11813.	11.2	13
10	Chiral Recognition of Flexible Melatonin Receptor Ligands Induced by Conformational Equilibria. Molecules, 2020, 25, 4057.	3.8	8
11	New classes of potent heparanase inhibitors from ligand-based virtual screening. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 1685-1696.	5.2	9
12	Antidepressant-like effects of pharmacological inhibition of FAAH activity in socially isolated female rats. European Neuropsychopharmacology, 2020, 32, 77-87.	0.7	22
13	Design and SAR Analysis of Covalent Inhibitors Driven by Hybrid QM/MM Simulations. Methods in Molecular Biology, 2020, 2114, 307-337.	0.9	12
14	The Control of Heparanase Through the Use of Small Molecules. Advances in Experimental Medicine and Biology, 2020, 1221, 567-603.	1.6	9
15	New Antimicrobials Targeting Bacterial RNA Polymerase Holoenzyme Assembly Identified with an in Vivo BRET-Based Discovery Platform. ACS Chemical Biology, 2019, 14, 1727-1736.	3.4	10
16	Pharmacokinetics, pharmacodynamics and safety studies on URB937, a peripherally restricted fatty acid amide hydrolase inhibitor, in rats. Journal of Pharmacy and Pharmacology, 2019, 71, 1762-1773.	2.4	9
17	Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR. European Journal of Medicinal Chemistry, 2019, 162, 507-524.	5.5	11
18	Tetrahydroquinoline Ring as a Versatile Bioisostere of Tetralin for Melatonin Receptor Ligands. Journal of Medicinal Chemistry, 2018, 61, 3726-3737.	6.4	15

#	Article	IF	Citations
19	Novel Symmetrical Benzazolyl Derivatives Endowed with Potent Anti-Heparanase Activity. Journal of Medicinal Chemistry, 2018, 61, 10834-10859.	6.4	19
20	Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity. Journal of Medicinal Chemistry, 2018, 61, 6918-6936.	6.4	30
21	Identification of Bivalent Ligands with Melatonin Receptor Agonist and Fatty Acid Amide Hydrolase (FAAH) Inhibitory Activity That Exhibit Ocular Hypotensive Effect in the Rabbit. Journal of Medicinal Chemistry, 2018, 61, 7902-7916.	6.4	18
22	Pharmacological inhibition of FAAH activity in rodents: A promising pharmacological approach for psychologicalâ€"cardiac comorbidity?. Neuroscience and Biobehavioral Reviews, 2017, 74, 444-452.	6.1	16
23	Metadynamics Simulations Distinguish Short- and Long-Residence-Time Inhibitors of Cyclin-Dependent Kinase 8. Journal of Chemical Information and Modeling, 2017, 57, 159-169.	5.4	51
24	Atropisomerism and Conformational Equilibria: Impact on PI3KÎ´ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs. Journal of Medicinal Chemistry, 2017, 60, 4304-4315.	6.4	15
25	Social stress contagion in rats: Behavioural, autonomic and neuroendocrine correlates. Psychoneuroendocrinology, 2017, 82, 155-163.	2.7	37
26	Metadynamics for Perspective Drug Design: Computationally Driven Synthesis of New Proteinâ€"Protein Interaction Inhibitors Targeting the EphA2 Receptor. Journal of Medicinal Chemistry, 2017, 60, 787-796.	6.4	32
27	Synthesis and characterization of the first inhibitor ofN-acylphosphatidylethanolamine phospholipase D (NAPE-PLD). Chemical Communications, 2017, 53, 12814-12817.	4.1	33
28	Antiproliferative and pro-apoptotic activity of melatonin analogues on melanoma and breast cancer cells. Oncotarget, 2017, 8, 68338-68353.	1.8	46
29	Exploiting Freeâ€Energy Minima to Design Novel EphA2 Proteinâ€"Protein Antagonists: From Simulation to Experiment and Return. Chemistry - A European Journal, 2016, 22, 8048-8052.	3.3	15
30	Cardioprotective effects of fatty acid amide hydrolase inhibitor URB694, in a rodent model of trait anxiety. Scientific Reports, 2016, 5, 18218.	3.3	18
31	Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase. Glycobiology, 2016, 26, 640-654.	2.5	58
32	Heparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases. Future Medicinal Chemistry, 2016, 8, 647-680.	2.3	146
33	Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors. Journal of Medicinal Chemistry, 2016, 59, 4651-4663.	6.4	29
34	Free-energy studies reveal a possible mechanism for oxidation-dependent inhibition of MGL. Scientific Reports, 2016, 6, 31046.	3.3	13
35	Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimerâ€™s Disease Agents. Journal of Medicinal Chemistry, 2016, 59, 6387-6406.	6.4	66
36	Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists. Molecules, 2015, 20, 17132-17151.	3.8	5

#	Article	IF	Citations
37	Amino Acid Derivatives as Palmitoylethanolamide Prodrugs: Synthesis, In Vitro Metabolism and In Vivo Plasma Profile in Rats. PLoS ONE, 2015, 10, e0128699.	2.5	23
38	Novel N-Acetyl Bioisosteres of Melatonin: Melatonergic Receptor Pharmacology, Physicochemical Studies, and Phenotypic Assessment of Their Neurogenic Potential. Journal of Medicinal Chemistry, 2015, 58, 4998-5014.	6.4	32
39	Pharmacokinetic and pharmacodynamic evaluation of ramelteon: an insomnia therapy. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1145-1156.	3.3	12
40	Quantum Mechanics/Molecular Mechanics Modeling of Covalent Addition between EGFRâ€"Cysteine 797 and N-(4-Anilinoquinazolin-6-yl) Acrylamide. Journal of Chemical Information and Modeling, 2015, 55, 589-599.	5.4	42
41	Therapeutic uses of melatonin and melatonin derivatives: a patent review (2012 â€" 2014). Expert Opinion on Therapeutic Patents, 2015, 25, 425-441.	5.0	46
42	Fatty acid amide hydrolase inhibitors: a patent review (2009 â€" 2014). Expert Opinion on Therapeutic Patents, 2015, 25, 1-20.	5.0	48
43	Î"5-Cholenoyl-amino acids as selective and orally available antagonists of the Ephâ€"ephrin system. European Journal of Medicinal Chemistry, 2015, 103, 312-324.	5.5	38
44	Antidepressant-like activity and cardioprotective effects of fatty acid amide hydrolase inhibitor URB694 in socially stressed Wistar Kyoto rats. European Neuropsychopharmacology, 2015, 25, 2157-2169.	0.7	27
45	Highly Potent and Selective MT₂ Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines. Journal of Medicinal Chemistry, 2015, 58, 7512-7525.	6.4	47
46	New coumarin-based fluorescent melatonin ligands. Design, synthesis and pharmacological characterization. European Journal of Medicinal Chemistry, 2015, 103, 370-373.	5.5	15
47	Synthesis and Characterization of New Bivalent Agents as Melatonin- and Histamine H3-Ligands. International Journal of Molecular Sciences, 2014, 15, 16114-16133.	4.1	7
48	Insights in the Mechanism of Action and Inhibition of N-Acylethanolamine Acid Amidase by Means of Computational Methods. Advances in Protein Chemistry and Structural Biology, 2014, 96, 219-234.	2.3	3
49	<scp>U</scp>ni<scp>PR</scp>129 is a competitive small molecule <scp>E</scp>phâ€ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. British Journal of Pharmacology, 2014, 171, 5195-5208.	5.4	43
50	Towards the development of 5-HT7 ligands combining serotonin-like and arylpiperazine moieties. European Journal of Medicinal Chemistry, 2014, 80, 8-35.	5.5	8
51	MT₁ and MT₂ Melatonin Receptors: Ligands, Models, Oligomers, and Therapeutic Potential. Journal of Medicinal Chemistry, 2014, 57, 3161-3185.	6.4	136
52	Synthesis, structure and inhibitory activity of a stereoisomer of oseltamivir carboxylate. Organic and Biomolecular Chemistry, 2014, 12, 1561.	2.8	18
53	Combining Ligand- and Structure-Based Approaches for the Discovery of New Inhibitors of the EPHA2â€"ephrin-A1 Interaction. Journal of Chemical Information and Modeling, 2014, 54, 2621-2626.	5.4	13
54	ST7612AA1, a Thioacetate-Ï‰(Î³-lactam carboxamide) Derivative Selected from a Novel Generation of Oral HDAC Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 8358-8377.	6.4	40

#	Article	IF	Citations
55	Structure-Based Virtual Screening of MT₂ Melatonin Receptor: Influence of Template Choice and Structural Refinement. Journal of Chemical Information and Modeling, 2013, 53, 821-835.	5.4	32
56	Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5290-5294.	2.2	3
57	Amino Acid Conjugates of Lithocholic Acid As Antagonists of the EphA2 Receptor. Journal of Medicinal Chemistry, 2013, 56, 2936-2947.	6.4	50
58	Synthesis of (E)-8-(3-Chlorostyryl)caffeine Analogues Leading to 9-Deazaxanthine Derivatives as Dual A_{2A} Antagonists/MAO-B Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 1247-1261.	6.4	45
59	Quantum Mechanics/Molecular Mechanics Modeling of Fatty Acid Amide Hydrolase Reactivation Distinguishes Substrate from Irreversible Covalent Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 2500-2512.	6.4	35
60	Homology Models of Melatonin Receptors: Challenges and Recent Advances. International Journal of Molecular Sciences, 2013, 14, 8093-8121.	4.1	40
61	Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor. Molecules, 2013, 18, 13043-13060.	3.8	13
62	MT₁â€Selective Melatonin Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Dynamics Investigation of Nâ€{[(3â€Oâ€Substituted)anilino]alkyl}amides. ChemMedChem, 2012, 7, 1954-1964.	3.2	24
63	Anxiolytic effects of the melatonin MT2 receptor partial agonist UCM765: Comparison with melatonin and diazepam. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 318-325.	4.8	60
64	Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. Journal of Medicinal Chemistry, 2012, 55, 2251-2264.	6.4	53
65	N-(2-Oxo-3-oxetanyl)carbamic Acid Esters as N-Acylethanolamine Acid Amidase Inhibitors: Synthesis and Structureâ€"Activity and Structureâ€"Property Relationships. Journal of Medicinal Chemistry, 2012, 55, 4824-4836.	6.4	48
66	Dibasic biphenyl H3 receptor antagonists: Steric tolerance for a lipophilic side chain. European Journal of Medicinal Chemistry, 2012, 48, 214-230.	5.5	11
67	Understanding the role of carbamate reactivity in fatty acid amide hydrolase inhibition by QM/MM mechanistic modelling. Chemical Communications, 2011, 47, 2517.	4.1	29
68	Toward the Definition of Stereochemical Requirements for MT₂-Selective Antagonists and Partial Agonists by Studying 4-Phenyl-2-propionamidotetralin Derivatives. Journal of Medicinal Chemistry, 2011, 54, 8362-8372.	6.4	24
69	Promotion of Non-Rapid Eye Movement Sleep and Activation of Reticular Thalamic Neurons by a Novel MT₂Melatonin Receptor Ligand. Journal of Neuroscience, 2011, 31, 18439-18452.	3.6	113
70	Melatonin Receptor Agonists: New Options for Insomnia and Depression Treatment. CNS Neuroscience and Therapeutics, 2011, 17, 733-741.	3.9	59
71	Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: Steric effects of N-alkyl chain on rat plasma and liver stability. European Journal of Medicinal Chemistry, 2011, 46, 4466-4473.	5.5	20
72	Bivalent ligand approach on N-{2-[(3-methoxyphenyl)methylamino]ethyl}acetamide: Synthesis, binding affinity and intrinsic activity for MT1 and MT2 melatonin receptors. Bioorganic and Medicinal Chemistry, 2011, 19, 4910-4916.	3.0	13

#	Article	IF	Citations
73	Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion. Mini-Reviews in Medicinal Chemistry, 2011, 11, 1019-1030.	2.4	37
74	Application of Computational Methods to the Design of Fatty Acid Amide Hydrolase (FAAH) Inhibitors Based on a Carbamic Template Structure. Advances in Protein Chemistry and Structural Biology, 2011, 85, 1-26.	2.3	10
75	Recent advances in the development of melatonin MT₁and MT₂receptor agonists. Expert Opinion on Therapeutic Patents, 2010, 20, 1059-1077.	5.0	53
76	Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion. Journal of Medicinal Chemistry, 2010, 53, 2038-2050.	6.4	49
77	Structural Fluctuations in Enzyme-Catalyzed Reactions: Determinants of Reactivity in Fatty Acid Amide Hydrolase from Multivariate Statistical Analysis of Quantum Mechanics/Molecular Mechanics Paths. Journal of Chemical Theory and Computation, 2010, 6, 2948-2960.	5.3	61
78	Synthesis and Structureâˆ'Activity Relationships of N-(2-Oxo-3-oxetanyl)amides as N-Acylethanolamine-hydrolyzing Acid Amidase Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 5770-5781.	6.4	53
79	Structureâ€"Property Relationships of a Class of Carbamateâ€Based Fatty Acid Amide Hydrolase (FAAH) Inhibitors: Chemical and Biological Stability. ChemMedChem, 2009, 4, 1495-1504.	3.2	40
80	Nâ€(Anilinoethyl)amides: Design and Synthesis of Metabolically Stable, Selective Melatonin Receptor Ligands. ChemMedChem, 2009, 4, 1746-1755.	3.2	30
81	The collisional behavior of ESIâ€generated protonated molecules of some carbamate FAAH inhibitors isosteres and its relationships with biological activity. Journal of Mass Spectrometry, 2009, 44, 561-565.	1.6	5
82	Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 639-643.	2.2	114
83	Selective N -acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 20966-20971.	7.1	206
84	Synthesis and structureâ€"activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity. Bioorganic and Medicinal Chemistry, 2008, 16, 9911-9924.	3.0	30
85	Identification of productive inhibitor binding orientation in fatty acid amide hydrolase (FAAH) by QM/MM mechanistic modelling. Chemical Communications, 2008, , 214-216.	4.1	65
86	Synthesis and Quantitative Structureâˆ'Activity Relationship of Fatty Acid Amide Hydrolase Inhibitors: Modulation at the N-Portion of Biphenyl-3-yl Alkylcarbamates. Journal of Medicinal Chemistry, 2008, 51, 3487-3498.	6.4	67
87	Melatonin Receptor Agonists: SAR and Applications to the Treatment of Sleep-Wake Disorders. Current Topics in Medicinal Chemistry, 2008, 8, 954-968.	2.1	59
88	N-(Substituted-anilinoethyl)amides: Design, Synthesis, and Pharmacological Characterization of a New Class of Melatonin Receptor Ligands. Journal of Medicinal Chemistry, 2007, 50, 6618-6626.	6.4	78
89	Identification of a Bioactive Impurity in a Commercial Sample of 6â€Methylâ€2â€pâ€Tolylaminobenzo[d][1,3]Oxazinâ€4â€One (URB754). Annali Di Chimica, 2007, 97, 887-894.	0.6	17
90	Synthesis, Enantiomeric Resolution, and Structureâ€"Activity Relationship Study of a Series of 10,11â€Dihydroâ€5Hâ€Dibenzo[a,d]cycloheptene MT₂ Receptor Antagonists. ChemMedChem, 2007, 2, 1741-1749.	3.2	11

#	Article	IF	Citations
91	Correlation between energetics of collisionally activated decompositions, interaction energy and biological potency of carbamate FAAH inhibitors. Journal of Mass Spectrometry, 2007, 42, 1624-1627.	1.6	9
92	URB602 Inhibits Monoacylglycerol Lipase andÂSelectively Blocks 2-Arachidonoylglycerol Degradation in Intact Brain Slices. Chemistry and Biology, 2007, 14, 1357-1365.	6.0	93
93	Pharmacological Characterization of Hydrolysis-Resistant Analogs of Oleoylethanolamide with Potent Anorexiant Properties. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 563-570.	2.5	79
94	Design and Synthesis ofN-(3,3-Diphenylpropenyl)alkanamides as a Novel Class of High-Affinity MT2-Selective Melatonin Receptor Ligands. Journal of Medicinal Chemistry, 2006, 49, 7393-7403.	6.4	25
95	Dibasic non-imidazole histamine H3 receptor antagonists with a rigid biphenyl scaffold. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 4063-4067.	2.2	25
96	Synthesis and biological evaluation of new non-imidazole H3-receptor antagonists of the 2-aminobenzimidazole series. Bioorganic and Medicinal Chemistry, 2006, 14, 1413-1424.	3.0	26
97	Reassessing the melatonin pharmacophoreâ€"Enantiomeric resolution, pharmacological activity, structure analysis, and molecular modeling of a constrained chiral melatonin analogue. Bioorganic and Medicinal Chemistry, 2006, 14, 3383-3391.	3.0	28
98	Synthesis and Structure-Activity Relationships of FAAH Inhibitors: Cyclohexylcarbamic Acid Biphenyl Esters with Chemical Modulation at the Proximal Phenyl Ring. ChemMedChem, 2006, 1, 130-139.	3.2	59
99	MT2 selective melatonin receptor antagonists: design and structure-activity relationships. Arkivoc, 2006, 2006, 8-16.	0.5	12
100	Validation of a histamine H3 receptor model through structureâ€"activity relationships for classical H3 antagonists. Bioorganic and Medicinal Chemistry, 2005, 13, 5647-5657.	3.0	41
101	Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nature Neuroscience, 2005, 8, 1139-1141.	14.8	210
102	Application of 3D-QSAR in the Rational Design of Receptor Ligands and Enzyme Inhibitors. Chemistry and Biodiversity, 2005, 2, 1438-1451.	2.1	9
103	Analysis of Structureâˆ'Activity Relationships for MT2Selective Antagonists by Melatonin MT1and MT2Receptor Models. Journal of Medicinal Chemistry, 2005, 48, 4049-4060.	6.4	75
104	Imidazole H3-antagonists: relationship between structure and ex vivo binding to rat brain H3-receptors. European Journal of Pharmaceutical Sciences, 2004, 23, 89-98.	4.0	13
105	Cyclohexylcarbamic Acid 3â€˜- or 4â€˜-Substituted Biphenyl-3-yl Esters as Fatty Acid Amide Hydrolase Inhibitors:Â Synthesis, Quantitative Structureâˆ'Activity Relationships, and Molecular Modeling Studies. Journal of Medicinal Chemistry, 2004, 47, 4998-5008.	6.4	255
106	Synthesis, biological activity, QSAR and QSPR study of 2-aminobenzimidazole derivatives as potent H3-antagonists. Bioorganic and Medicinal Chemistry, 2004, 12, 663-674.	3.0	49
107	Synthesis, pharmacological evaluation, and structureâ€"activity relationships of benzopyran derivatives with potent SERM activity. Bioorganic and Medicinal Chemistry, 2004, 12, 3763-3782.	3.0	23
108	Tricyclic Alkylamides as Melatonin Receptor Ligands with Antagonist or Inverse Agonist Activity. Journal of Medicinal Chemistry, 2004, 47, 4202-4212.	6.4	30

#	Article	IF	Citations
109	The role of HB-donor groups in the heterocyclic polar fragment of H3-antagonists.. Il Farmaco, 2003, 58, 891-899.	0.9	9
110	Synthesis and structureâ€"activity relationships of a series of pyrrole cannabinoid receptor agonists. Bioorganic and Medicinal Chemistry, 2003, 11, 3965-3973.	3.0	28
111	Design, Synthesis, and Structureâˆ'Activity Relationships of Alkylcarbamic Acid Aryl Esters, a New Class of Fatty Acid Amide Hydrolase Inhibitors. Journal of Medicinal Chemistry, 2003, 46, 2352-2360.	6.4	160
112	Three-Dimensional Quantitative Structureâˆ'Activity Relationship Studies on Selected MT1 and MT2 Melatonin Receptor Ligands:â€‰ Requirements for Subtype Selectivity and Intrinsic Activity Modulation. Journal of Medicinal Chemistry, 2003, 46, 1429-1439.	6.4	57
113	Synthesis and Three-Dimensional Quantitative Structure-Activity Relationship Analysis of H3 Receptor Antagonists Containing a Neutral Heterocyclic Polar Group. Drug Design and Discovery, 2003, 18, 65-79.	0.3	6
114	Strategies Leading To MT2 Selective Melatonin Receptor Antagonists. Advances in Experimental Medicine and Biology, 2003, 527, 577-585.	1.6	1
115	Synthesis and three-dimensional quantitative structure-activity relationship analysis of H3 receptor antagonists containing a neutral heterocyclic polar group. Drug Design and Discovery, 2003, 18, 65-79.	0.3	1
116	Synthesis and Three-Dimensional Quantitative Structure-Activity Relationship Analysis of H3 Receptor Antagonists Containing a Neutral Heterocyclic Polar Group. Drug Design and Discovery, 2003, 18, 65-79.	0.3	1
117	2-N-Acylaminoalkylindoles:â€‰ Design and Quantitative Structureâˆ'Activity Relationship Studies Leading to MT2-Selective Melatonin Antagonists. Journal of Medicinal Chemistry, 2001, 44, 2900-2912.	6.4	56
118	Synthesis, pharmacological characterization and QSAR studies on 2-substituted indole melatonin receptor ligands. Bioorganic and Medicinal Chemistry, 2001, 9, 1045-1057.	3.0	45
119	Structureâ€"property relationships on histamine H3-antagonists: binding of phenyl-substituted alkylthioimidazole derivatives to rat plasma proteins. Il Farmaco, 2000, 55, 239-245.	0.9	1
120	Synthesis and biological assays of new H3-antagonists with imidazole and imidazoline polar groups. Il Farmaco, 2000, 55, 27-34.	0.9	12
121	Experimental and theoretical analysis of the interaction of (Â±)-cis-ketoconazole with Î²-cyclodextrin in the presence of (+)-l-Tartaric acid. Journal of Pharmaceutical Sciences, 1999, 88, 599-607.	3.3	34
122	2-[N-Acylamino(C1âˆ'C3)alkyl]indoles as MT1Melatonin Receptor Partial Agonists, Antagonists, and Putative Inverse Agonists. Journal of Medicinal Chemistry, 1998, 41, 3624-3634.	6.4	101
123	Melatonin Receptor Ligands:Â Synthesis of New Melatonin Derivatives and Comprehensive Comparative Molecular Field Analysis (CoMFA) Study. Journal of Medicinal Chemistry, 1998, 41, 3831-3844.	6.4	71
124	H3-Receptor Antagonists:â€‰ Synthesis and Structureâˆ'Activity Relationships of Para- and Meta-Substituted 4(5)-Phenyl-2-[[2-[4(5)-imidazolyl]ethyl]thio]imidazoles. Journal of Medicinal Chemistry, 1997, 40, 2571-2578.	6.4	20
125	Conformationally Restrained Melatonin Analogues:Â Synthesis, Binding Affinity for the Melatonin Receptor, Evaluation of the Biological Activity, and Molecular Modeling Study. Journal of Medicinal Chemistry, 1997, 40, 1990-2002.	6.4	73